AstraZeneca’s chief executive, Pascal Soriot, has reportedly said that he would like to shift the company’s stock market listing from the UK to the US.
The boss of Britain’s most valuable listed company has spoken privately about a preference to move the listing to New York, the Times reported. It added that he had also considered moving the company’s domicile.
